<DOC>
	<DOCNO>NCT02558933</DOCNO>
	<brief_summary>The flavonoid epigallocatechin gallate ( EGCG ) modulator neuronal plasticity useful neurodevelopmental disease . A recent study show EGCG promise tool cognitive health relate quality life improvement Down 's syndrome . The objective determine efficacy EGCG therapeutic candidate improvement cognitive performance FAS patient . Pre post study , non randomize , control without placebo , evaluate efficacy EGCG . It pilot study cohort 40 FAS child , 7 an 14 year old . An oral dose 9 mg/Kg/day administer 1 year , 6 control visit 6 month finish treatment .</brief_summary>
	<brief_title>Epigallocatechin Gallate ( EGCG ) Improve Cognitive Performance Foetal Alcohol Syndrome ( FAS ) Children</brief_title>
	<detailed_description>Background 1 % child present prenatal alcohol exposure relate disorder . Prevalence consumption increase every year . In previous study Barcelona , 45.5 % ethanol positive meconium detect , biomarker maternal consumption alcohol pregnancy . The serious clinical picture include facial , mental cognitive disorder Foetal Alcohol Syndrome ( FAS ) . Spain second country adoption East Europe , consumption alcohol pregnancy important . The prevention FAS avoid consumption alcohol pregnancy treatment deleterious effect neurodevelopment . The flavonoid epigallocatechin gallate ( EGCG ) modulator neuronal plasticity useful neurodevelopmental disease . A recent study show EGCG promise tool cognitive health relate quality life improvement Down 's syndrome . Objective To determine efficacy EGCG therapeutic candidate improvement cognitive performance FAS patient . Methodology Pre post study , non randomize , control without placebo , evaluate efficacy EGCG . It pilot study cohort 40 FAS child , 7 an 14 year old . An oral dose 9 mg/Kg/day administer 1 year , 6 control visit 6 month finish treatment . Instrumentalization 1 . Cognitive neuropsychologic diagnostic scale FAS 2 . Determination value oxidative stress 3 . Determination control biomarkers treatment</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>1 . FAS diagnose child 7 14 y.o . 2 . Included previous cohort ( ALMAR ) 3 . Informed consent parent 1 . Refuse parent participate 2 . Unfulfillment inclusion criterion 3 . Any condition child prevent FAS diagnostics test application</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Fetal Alcohol Syndrome</keyword>
	<keyword>Prenatal exposure</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Epigallocatechin gallate</keyword>
</DOC>